Indicator | BG | CZ | HU | LV | PL | RO | SI | SK |
---|---|---|---|---|---|---|---|---|
Reference year | 2008 | 2008 | 2009 | 2008 | 2009 | 2008 | 2007 | 2009 |
Sustainable funding | ||||||||
 HC system | SHI | SHI | SHI | SHI | SHI | SHI | SHI | SHI |
 TPE in % of THE | 33.4 % (0.0 pp) | 20.4 % (-4.4 pp) | 32.5 % (+1.5 pp) | 19.4 % (-2.6 pp) | 22.9 % (-4.3 pp) | 25.0 % (-3.2 pp) | 19.6 % (-1.1 pp) | 26.6 % (-3.2 pp) |
 TPE share  (CEE-10 comparison) | +9.0 pp | −4.0 pp | +6.7 pp | −5.0 pp | −1.5 pp | +0.6 pp | - 6.0 pp | +3.2 pp |
 TPE per capita | € 109.9 (+50.3 %) | € 205.6 (+17.1 %) | € 229.4 (+0.8 %) | € 134.3 (+66.6 %) | € 134.5 (+11.7 %) | € 92.2 (+59.1 %) | € 264.0 (+12.0 %) | € 283.5 (+56.6 %) |
 TPE/capita  (CEE-10 comparison) | −39.1 % | +14.0 % | +35.3 % | −25.6 % | −16.5 % | −48.9 % | +56.9 % | +47.0 % |
Affordability | ||||||||
 Private HE/THE | 41.8 % (+6.5 %) | 17.5 % (+37.5 %) | 34.3 % (+13.5 %) | 37.4 % (-12.7 %) | 28.2 % (-6.0 %) | 18.0 % (-6.2 %) | 28.1 % (+4.6 %) | 34.3 % (+8.3 %) |
 Private HE/THE  (CEE-10 compar.) | +13.6 pp | −10.8 pp | +4.7 pp | +9.2 pp | - 0.1 pp | −10.3 pp | −2.2 pp | +4.0 pp |
 Private PE/TPE | 81.7 % (+4.8 %) | 38.4 % (+56.9 %) | 51.6 % (37.7 %) | 62.2 % (-9.4 %) | 61.4 % (0 %) | 55.0 % (+4.8 %) | 40.1 % (+2.9 %) | 30.2 % (+11.3 %) |
 Private PE/TPE  (CEE-10 comp.) | +27.8 pp | −15.5 pp | −2.9 pp | +8.3 pp | +7.8 pp | +1.2 pp | −13.7 pp | −25.2 pp |
 Informal pays | Yes, extensive | Yes | Yes | Yes, extensive | Yes | Yes, large scale | No | Yes |
 Medicine prices | n.a. | € 5.09 (-71.4 %) | € 6.91 (-61.2 %) | € 4.23 (-76.2 %) | € 4.54 (-74.5 %) | n.a. | € 12.34 (-30.8 %) | n.a. |
 Co-pays (out-patient) | No PF | PF | PF | No PF | PF for some indications | No PF | No PF | PF |
%: 0Â %, >25Â %, >50Â % | No fixed R rates | %: 0Â %, 10Â %, 30Â %; 25Â %, 45Â %, 75Â % | %: 0Â %, 10Â %, 25Â %, 50Â %, 25Â % | %: 0Â %, 30Â %, 50Â % | %: 0Â %, 10Â %, 50Â % | %: 0Â %, 25Â %, 75Â % | %: no fixed R rates | |
No D | No D | No D | No D | No D | No D | No D | No D | |
 Changes in co-pays | No | Yes | Yes, increase | No, but planned (90 % R rate to be abolished) | No since mid-1990-ties | No | No | Yes, decrease in PF in 10/2006 |
 Co-pay exempt. | None | None | Yes | Yes | Yes | Yes, see comment | Yes | Yes |
 De-listings | No, see comment | Not known | Yes, see comment | See comment | Yes | See comment | No | No major delisting |
 Co-pays (in-patient) | No co-payment | No co-payment | No co-payment | No co-payment | No co-payment | No co-payment | No co-payment | No co-payment |
 VAT on medicines | 20 % (20 %) | 9 % (19 %) | 5 % (20 %) | 5 % (18 %), planned increase from 1/2009 | 7 % (22) | 9 % (19 %) | 8.5 % (20 %) | 10 % (19 %) |
 OTC market | 22 % | 26.8 % | 15.8 % | n.a. | 25.8 % | 22.4 % | 6.7 % | 25.8 % |
Availability and accessibility | ||||||||
 No. of medicines | 5,8302006 | 7,8802006 | 5,525 2006 | n.a. | (8,0892005) | 6,7112007 | 2,7912006 | 19,693 November 2006 |
4,4812006 | 4,1302006 | 3,1442006 | 5,7142007 | 4,2752006 | ≈4,0002007 | n.a. | 19,320November 2006 | |
1,598 | 6,9882006 | 2,8862006 | 2,3372007 | 2,7492006 | 5,7912007 | 2,6602006 | 17,804November 2006 | |
See comment | Â | See comment | See comment | See comment | See comment | See comment | See comment | |
 Pharmacies | 4,299/1,7952006 | 2,520/4,0962007 | ≈2,500/≈4,0002010 | 899/2,2092007 | 10,632/3,5852007 | 5,660/3,7332007 | 271/7,3842005 | 1,523/3,528Oct. 2006 |
 OTC sale outside pharmacies permitted | Yes | Yes | Yes | No | No | Yes, but pharmacist must be present | Yes | No |
Rational selection and use of medicines | ||||||||
 INN prescribing | Yes, indicative | Yes, indicative | Yes, indicative | Yes, indicative | Yes, indicative | Yes, indicative | Yes, indicative | Yes, indicative |
 Generic substitution | No, not allowed | Yes, indicative | Yes, indicative | Yes, obligatory | Yes, indicative | Yes, indicative | Yes, indicative | Yes, obligatory |
 Ref. price syst. | Yes, ATC 5 | Yes, ATC 4 + 5 | Yes, ATC 4 + 5 | Yes, ATC 3,4 + 5 | Yes, ATC 3,4 + 5 | Yes, ATC 5 | Yes, ATC 4 | Yes, ATC 4 + 5 |
 Generic market | See comment | 55 %/35 %2005 | 42 %/26 %2005 | No data | No data | ≈70 %/≈40 %e | 70 %/38 %2005 | 65 %/48 %2005 |
 Prescription monitoring | Yes, but limited | Yes | Yes, but limitations in enforcement | Yes | Yes, but limitations in enforcement | Yes, but limitations in enforcement | Yes | Yes |